Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313722 | 1.00 | L3MBTL1 (0.43) | L3MBTL1NEU1 | |
| SCHEMBL20173804 | 0.85 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL31135779 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL19589624 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL29723135 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL12473304 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL17354966 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL13760844 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL21914991 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 | |
| SCHEMBL12138167 | 0.81 | L3MBTL1 (0.53) | L3MBTL1NEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050304-B2 | Methods of treatment using glycopegylated G-CSF | RATIOPHARM GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20100120666-A1 | METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF | BIOGENERIX AG (DE) | 2010-05-13 | — | — | US | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120666-A1 | METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF | CSF3R, CSF1R, SIGLEC7 | L3MBTL1 1390/4885NEU1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.